Physician profile
Daniel W Mclaughlin
NPI 1295769842
$3,081.22
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $366 · 2020: $546 · 2021: $390 · 2022: $448 · 2023: $625 · 2024: $707.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,331.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,331.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $840.19 | 2021-2024 | |
| Astrazeneca Pharmaceuticals Lp | $318.36 | 2019-2024 | Airsupra, Farxiga |
| Pfizer INC. | $298.36 | 2019-2024 | |
| Allergan, INC. | $248.04 | 2019-2020 | |
| Glaxosmithkline, LLC. | $185.32 | 2019-2023 | Arexvy, Trelegy Ellipta, Shingrix |
| Amgen INC. | $143.01 | 2019-2021 | |
| Lilly USA, LLC | $133.22 | 2019-2024 | Mounjaro, Jardiance |
| Novo Nordisk INC | $103.46 | 2020-2024 | Ozempic, Rybelsus, Wegovy |
| E.R. Squibb & Sons, L.L.C. | $102.30 | 2021 | |
| Amarin Pharma, INC. | $76.01 | 2020 | |
| Edwards Lifesciences Corporation | $73.06 | 2023-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Genzyme Corporation | $65.18 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $61.77 | 2019-2023 | Ajovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.51 | 2019-2022 | |
| Axsome Therapeutics, INC. | $48.28 | 2023-2024 | Auvelity |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $36.93 | 2020-2024 | Orencia |
| Boston Scientific Corporation | $35.02 | 2022-2024 | |
| Astellas Pharma US INC | $30.52 | 2023 | Veozah |
| Daiichi Sankyo INC. | $22.96 | 2020 | |
| Xeris Pharmaceuticals, INC. | $22.43 | 2022 | |
| Impel Pharmaceuticals INC. | $21.77 | 2022 | |
| Corium, LLC | $20.70 | 2023-2024 | Azstarys |
| Alnylam Pharmaceuticals INC. | $20.24 | 2023 | Amvuttra |
| Abbott Laboratories | $19.13 | 2023 | Freestyle Libre 3 |
| Ironshore Pharmaceuticals INC. | $18.43 | 2023 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $17.79 | 2021 | |
| Pharming Healthcare, INC. | $14.35 | 2022 | |
| Genentech USA, INC. | $13.26 | 2021 | |
| Medtronic, INC. | $12.81 | 2023 | Minimed 780g |
| Horizon Therapeutics Plc | $12.04 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $11.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Mclaughlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.